uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung

  • End date
    Oct 21, 2023
  • participants needed
  • sponsor
    Rigshospitalet, Denmark
Updated on 21 January 2021
lung cancer
lung carcinoma


uPAR PET/CT as a prognostic marker in non-small cell lung cancer.


Study I: uPAR PET/CT with 68Ga-NOTA-AE105 will be evaluated as a prognostic tool in patients with non-small cell lung cancer (NSCLC) (stage IV (Ia) operable disease (Ib)) by observer-blinded readings and compared to the prognostic performance of FDG PET/CT and prognostic biomarkers as uPAR.

Furthermore, uPAR PET/CT will be evaluated in a pilot study in patients with malignant pleural mesothelioma (MPM) (Study II) and large cell neuroendocrine carcinoma of the lung (LCNEC) (Study III) and correlated with immunohistochemical uPAR expression.

Condition Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma, Pleural Mesothelioma, Large Cell Neuroendocrine Carcinoma of the Lung, nsclc
Treatment 68Ga-NOTA-AE105 PET/CT
Clinical Study IdentifierNCT02755675
SponsorRigshospitalet, Denmark
Last Modified on21 January 2021


Yes No Not Sure

Inclusion Criteria

Study I
Histologically verified NSCLC (Study I)
Stage IV disease
Operable disease
The participants must be capable of understanding and giving full informed written consent
Study II
Histologically verified MPM (Study II)
The participants must be capable of understanding and giving full informed written consent
Study III
Histologically verified LCNEC (Study III)
The participants must be capable of understanding and giving full informed written consent

Exclusion Criteria

Study I, II, III
Lactation/breast feeding
Treatment with neoadjuvant chemotherapy
Weight above 140 kg
Allergy to 68Ga-NOTA-AE105
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note